From the Journals
Clinical Guidelines
Conference News
Evolocumab Reduced CV Events in Diabetes
Subgroup analysis of the VESALIUS-CV trial supports earlier intensive lipid lowering
A global trial involving over 12,000 patients demonstrated that the PCSK9 inhibitor evolocumab significantly reduces the risk of major cardiovascular events in individuals with diabetes who do not have known significant atherosclerosis. Conducted at 774 sites across 33 countries, the study showed evolocumab reduced LDL cholesterol levels and resulted in a 2% lower incidence of primary cardiovascular events compared to placebo. Lead researcher Nicholas A. Marston highlights the potential for setting lower LDL targets in high-risk patients.
